 SAN DIEGO, Nov. 10, 2020 GLOBE NEWSWIRE -- TRACON Pharmaceuticals NASDAQ:TCON, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced financial results for the third quarter ended September 30, 2020. The Company will host a conference call and webcast today at 4:30 PM Eastern Time 1:30 PM Pacific Time. 